Axillary Treatment Management in Breast Cancer during COVID-19 Pandemic (Association between ACOSOG Z0011 Criteria and OSNA Test).
Giacomo AneddaFederico CappellacciGian Luigi CanuStefania FarrisPietro Giorgio CalòMassimo DessenaFabio MedasPublished in: Journal of personalized medicine (2023)
The outbreak of the SARS-COVID-2 pandemic (COVID-19) had a significant effect on the organisation of healthcare systems. Surgical units saw a significant reduction in the volume of surgical procedures performed, with lengthening waiting lists as a consequence. We assessed the surgical activity in relation to breast cancer that took place at the University Hospital of Cagliari, Italy, from February 2018 to March 2022. Two phases were identified based on the epidemiological circumstances: Phase 1-February 2018 to February 2020; Phase 2-March 2020 to March 2022. The surgery performed in the two phases was then compared. All the patients in our sample underwent a breast surgical procedure involving a lymph node biopsy using OSNA associated with the ACOSOG Z0011 criteria. In the study period overall at our facility, there were 4214 procedures, 417 of which involved breast surgery. In Phase 2, 91 procedures were performed using the OSNA method and ACOSOG Z0011 criteria, enabling the intraoperative staging of axillary nodes. Axillary treatment in breast cancer using this approach resulted in a significant reduction in the number of reoperations for the radicalisation of metastatic sentinel lymph nodes.
Keyphrases
- lymph node
- sentinel lymph node
- neoadjuvant chemotherapy
- minimally invasive
- healthcare
- end stage renal disease
- chronic kidney disease
- coronavirus disease
- ultrasound guided
- newly diagnosed
- squamous cell carcinoma
- ejection fraction
- small cell lung cancer
- combination therapy
- coronary artery disease
- early stage
- replacement therapy
- young adults
- patient reported outcomes
- peritoneal dialysis
- breast cancer risk
- atrial fibrillation